Liposomal compositions for enhanced retention of bioactive agents

• US 5,595,756 A
• Filed: 12/22/1993
• Issued: 01/21/1997
• Est. Priority Date: 12/22/1993
• Status: Expired due to Term

• Current Assignee: University of British Columbia
• Original Assignee: Inex Pharmaceuticals Corporation, The University of British Columbia
• Inventors: Boman, Nancy L., Mayer, Lawrence D., Cullis, Pieter R., Bally, Marcel B.
• Primary Examiner(s): Kishore, Gollamudi S.
• Application Number:
  US08/172,140
• Time in Patent Office: 1,126 Days
• Field of Search: 424/450, 428/402.2, 264/4.1, 264/4.3
• US Class Current: 424/450
• CPC Class Codes: A61K 9/1272 with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids with cholesterol as the only non-phosphatidyl surfactant A61K9/127; lipids as modifying agent A61K47/543

Abstract

Liposomal compositions encapsulating bioactive agents and having improved circulation longevity of the agents are disclosed. Such liposomes combine a low pH of the solution in which a bioactive agent is entrapped and a sugar-modified lipid or an amine-bearing lipid, the combination of which enhances the retention of the encapsulated bioactive agent and thereby promotes circulation longevity. The present invention also discloses methods of making and using such compositions.

Claims

1. A composition comprising liposomes having encapsulated therein both a bioactive agent and a buffered solution having a pH of 2 to 3, said liposomes containing a sugar-modified lipid which is a ganglioside and cerebroside in an amount of about 10 mol percent.

2. A composition according to claim 1 wherein said solution is pH 2.

3. A composition according to claim 1 wherein said sugar-modified lipid is a ganglioside selected from the group consisting of G_M1,G_M2 and G_M3.

4. A composition according to claim 3 wherein said bioactive agent is an anticancer agent.

5. A composition according to claim 3 wherein said solution is buffered with citrate, maleate or glutamate.

6. A composition according to claim 3, further comprising a pharmaceutically acceptable carrier or diluent.

9. A method for treating cancer in a warm-blooded animal, comprising administering a therapeutically effective amount of a composition according to claim 4 wherein said bioactive agent is an anticancer agent.

7. A composition comprising liposomes produced by

(a) hydrating a lipid film in a buffered first solution having a pH of 2 to 3 to yield liposomes, said lipid film containing a sugar-modified lipid which is a ganglioside and cerebroside in an amount of about 10 mol percent;

(b) contacting said liposomes with a second solution, said second solution containing a bioactive agent to provide a liposomal bioactive agent mixture;

(c) increasing the pH of said mixture in step (b) to a pH not above the pK_a of the bioactive agent to provide a liposomal mixture having a pH differential; and

(d) incubating said mixture having a pH differential under conditions and for a time sufficient to promote entrapping of said bioactive agent by said liposomes, thereby producing liposomes that encapsulate a bioactive agent and that contain a sugar-modified lipid ganglioside and cerebroside in an amount of about 10 mol percent.

8. A composition according to claim 7 in combination with a pharmaceutically acceptable carrier or diluent.

10. A method for treating cancer in a warm-blooded animal, comprising administering a therapeutically effective amount of a composition according to claim 8 wherein said bioactive agent is an anticancer agent.